Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Oral COVID-19 Antiviral Uptake Among a Highly Vaccinated US Cohort of Adults With SARS-CoV-2 Infection Between December 2021 and October 2022.

Autor: Shen Y; Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, New York, USA.; Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, New York, USA., Robertson MM; Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, New York, USA.; Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, New York, USA., Kulkarni SG; Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, New York, USA., Puzniak L; Pfizer, Inc., Collegeville, Pennsylvania, USA., Zamparo JM; Pfizer, Inc., Collegeville, Pennsylvania, USA., Allen KE; Pfizer, Inc., Collegeville, Pennsylvania, USA., Porter TM; Pfizer, Inc., Collegeville, Pennsylvania, USA., Qasmieh SA; Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, New York, USA.; Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, New York, USA., Grov C; Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, New York, USA.; Department of Community Health and Social Sciences, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, New York, USA., Srivastava A; Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, New York, USA.; Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, New York, USA., Zimba R; Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, New York, USA.; Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, New York, USA., McLaughlin JM; Pfizer, Inc., Collegeville, Pennsylvania, USA., Nash D; Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, New York, USA.; Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, New York, USA.

Publikováno v: Open forum infectious diseases [Open Forum Infect Dis] 2023 Dec 21; Vol. 11 (2), pp. ofad674. Date of Electronic Publication: 2023 Dec 21 (Print Publication: 2024).

Assessment of retrospective collection of EQ-5D-5L in a US COVID-19 population.

Autor: Sun X; Clinical Trial Services, CVS Health, Woonsocket, RI, USA. xiaowu.sun@cvshealth.com., Di Fusco M; Pfizer Inc, Health Economics and Outcomes Research, New York, NY, USA., Puzniak L; Pfizer Inc, MDSCA Vaccines, Collegeville, PA, USA., Coetzer H; Clinical Trial Services, CVS Health, Woonsocket, RI, USA., Zamparo JM; Pfizer Inc, Groton, CT, USA., Tabak YP; Clinical Trial Services, CVS Health, Woonsocket, RI, USA., Cappelleri JC; Pfizer Inc, Statistical Research and Data Science Center, Groton, CT, USA.

Publikováno v: Health and quality of life outcomes [Health Qual Life Outcomes] 2023 Sep 08; Vol. 21 (1), pp. 103. Date of Electronic Publication: 2023 Sep 08.

Determinates of Clostridioides difficile infection (CDI) testing practices among inpatients with diarrhea at selected acute-care hospitals in Rochester, New York, and Atlanta, Georgia, 2020-2021.

Autor: Fridkin SK; Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, Georgia.; Rollins School of Public Health, Emory University, AtlantaGeorgia., Onwubiko UN; Rollins School of Public Health, Emory University, AtlantaGeorgia., Dube W; Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, Georgia., Robichaux C; Division of Biomedical Informatics, Department of Medicine, Emory University, Atlanta, Georgia., Traenkner J; Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, Georgia., Goodenough D; Foundation for Atlanta Veterans' Education and Research, Decatur, Georgia.; Atlanta Veterans' Affairs Medical Center, Decatur, Georgia.; Georgia Emerging Infections Program, Atlanta, Georgia., Angulo FJ; Medical Development and Scientific/Clinical Affairs, Pfizer Vaccines, Collegeville, Pennsylvania., Zamparo JM; Medical Development and Scientific/Clinical Affairs, Pfizer Vaccines, Collegeville, Pennsylvania., Gonzalez E; Medical Development and Scientific/Clinical Affairs, Pfizer Vaccines, Collegeville, Pennsylvania., Khanna S; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota., Myers C; Center for Community Health and Prevention, University of Rochester Medical Center, Rochester, New York.; Infectious Diseases Division, University of Rochester Medical Center, Rochester, New York., Dumyati G; Center for Community Health and Prevention, University of Rochester Medical Center, Rochester, New York.; Infectious Diseases Division, University of Rochester Medical Center, Rochester, New York.

Publikováno v: Infection control and hospital epidemiology [Infect Control Hosp Epidemiol] 2023 Jul; Vol. 44 (7), pp. 1085-1092. Date of Electronic Publication: 2022 Sep 14.

Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System.

Autor: Tartof SY; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena.; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California., Slezak JM; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena., Puzniak L; Pfizer Inc, Collegeville, Pennsylvania., Hong V; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena., Frankland TB; Kaiser Permanente Hawaii Center for Integrated Health Care Research, Honolulu., Xie F; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena., Ackerson BK; Southern California Permanente Medical Group, Harbor City., Takhar H; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena., Ogun OA; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena., Simmons S; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena., Zamparo JM; Pfizer Inc, Groton, Connecticut., Tseng HF; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena., Jodar L; Pfizer Inc, Collegeville, Pennsylvania., McLaughlin JM; Pfizer Inc, Collegeville, Pennsylvania.

Publikováno v: JAMA network open [JAMA Netw Open] 2023 Jan 03; Vol. 6 (1), pp. e2251833. Date of Electronic Publication: 2023 Jan 03.